米氮平
引用

1 2 3 4 5 6  Timmer, CJ; Sitsen, JM; Delbressine, LP. . Clinical Pharmacokinetics. June 2000, 38 (6): 461–74. PMID 10885584. doi:10.2165/00003088-200038060-00001.
1 2 3 4 5 6  . DailyMed. Organon Pharmaceuticals USA. October 2012  [24 October 2013]. （原始内容存档于2021-01-10）.
1 2 3 4 5  . TGA eBusiness Services. alphapharm. 25 October 2011  [15 October 2013]. （原始内容存档于2020-09-20）.
1 2 3 4 5  . electronic Medicines Compendium. Sandoz Limited. 20 March 2013  [24 October 2013]. （原始内容 (PDF)存档于2013-10-29）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  Anttila, S. A.; Leinonen, E. V. . CNS drug reviews. 2001, 7 (3): 249–264. ISSN 1080-563X. PMC 6494141 . PMID 11607047. doi:10.1111/j.1527-3458.2001.tb00198.x.
1 2 3 4  Brayfield, A (编). . Martindale: The Complete Drug Reference (The Royal Pharmaceutical Society of Great Britain). 30 January 2013  [3 November 2013]. （原始内容存档于2020-03-12）.
1 2  Gorman, JM. . J Clin Psychiatry. 1999,. 60 Suppl 17: 9–13; discussion 46–8. PMID 10446735.
↑  Benjamin, S; Doraiswamy, PM. . Expert Opinion on Pharmacotherapy. July 2011, 12 (10): 1623–32  [2015-08-31]. PMID 21644844. doi:10.1517/14656566.2011.585459. （原始内容存档于2022-05-04）.
↑  Goodnick, PJ; Puig, A; DeVane, CL; Freund, BV. . J Clin Psychiatry. July 1999, 60 (7): 446–8. PMID 10453798. doi:10.4088/JCP.v60n0705.
1 2 3 4  Croom, KF; Perry, CM; Plosker, GL. . CNS Drugs. 2009, 23 (5): 427–52. PMID 19453203. doi:10.2165/00023210-200923050-00006.
↑  Muehlbacher, M; Nickel, MK; Nickel, C;  et al. . Journal of Clinical Psychopharmacology. December 2005, 25 (6): 580–3  [2015-08-31]. PMID 16282842. doi:10.1097/01.jcp.0000186871.04984.8d. （原始内容存档于2015-11-27）.  引文格式1维护：显式使用等标签 (link)
↑  Koran, LM; Quirk, T; Lorberbaum, JP; Elliott, M. . J Clin Psychopharmacol. October 2001, 21 (5): 537–9. PMID 11593084. doi:10.1097/00004714-200110000-00016. [不可靠的醫學來源？]
↑  Carpenter, LL; Leon, Z; Yasmin, S; Price, LH. . Ann Clin Psychiatry. June 1999, 11 (2): 81–6. PMID 10440525. doi:10.3109/10401239909147053. [不可靠的醫學來源？]
↑  Carli, V; Sarchiapone, M; Camardese, G; Romano, L; DeRisio, S. . Arch. Gen. Psychiatry. July 2002, 59 (7): 661–2. PMID 12090820. doi:10.1001/archpsyc.59.7.661. [不可靠的醫學來源？]
↑  Landowski, J. . Psychiatria Polska. 2002, 36 (6 Suppl): 125–30. PMID 12647431 （波兰语）.
↑  Chinuck, RS; Fortnum, H; Baldwin, DR. . Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association. December 2007, 20 (6): 526–37. PMID 18001374. doi:10.1111/j.1365-277X.2007.00824.x.
↑  Davis, MP; Khawam, E; Pozuelo, L; Lagman, R. . Expert Review of Anticancer Therapy. August 2002, 2 (4): 365–76. PMID 12647979. doi:10.1586/14737140.2.4.365.
↑  Hartmann, PM. . Am Fam Physician. January 1999, 59 (1): 159–61. PMID 9917581.
↑  Jindal, RD. . CNS Drugs. 2009, 23 (4): 309–29. PMID 19374460. doi:10.2165/00023210-200923040-00004.
↑  Nutt, DJ. . Human Psychopharmacology. June 2002,. 17 Suppl 1: S37–41. PMID 12404669. doi:10.1002/hup.388.
1 2  Li, TC; Shiah, IS; Sun, CJ; Tzang, RF; Huang, KC; Lee, WK. . The Journal of ECT. June 2011, 27 (2): 165–7  [2015-08-31]. PMID 21602639. doi:10.1097/YCT.0b013e3181e63346. （原始内容存档于2013-05-09）.
↑  Kast, RE; Foley, KF. . Eur J Cancer Care (Engl). July 2007, 16 (4): 351–4. PMID 17587360. doi:10.1111/j.1365-2354.2006.00760.x.
↑  Twycross, R; Greaves, MW; Handwerker, H;  et al. . QJM : Monthly Journal of the Association of Physicians. January 2003, 96 (1): 7–26  [2015-08-31]. PMID 12509645. doi:10.1093/qjmed/hcg002. （原始内容存档于2021-01-14）.  引文格式1维护：显式使用等标签 (link)
↑  Greaves, MW. . Dermatologic Therapy. 2005, 18 (4): 323–7. PMID 16297004. doi:10.1111/j.1529-8019.2005.00036.x.
↑  Colombo, B; Annovazzi, PO; Comi, G. . Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. October 2004,. 25 Suppl 3: S171–5. PMID 15549531. doi:10.1007/s10072-004-0280-x.
↑  Tajti, J; Almási, J. . Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology. June 2006, 8 (2): 67–72. PMID 17073214 （匈牙利语）.
↑  Kohler, M; Bloch, KE; Stradling, JR. . Expert Opinion on Investigational Drugs. May 2009, 18 (5): 647–56. PMID 19388881. doi:10.1517/13543780902877674.
↑  Marshall, NS; Yee, BJ; Desai, AV; Buchanan, PR; Wong, KK; Crompton, R; Melehan, KL; Zack, N; Rao, SG; Gendreau, RM; Kranzler, J; Grunstein, RR. . Sleep. June 2008, 31 (6): 824–31. PMC 2442407 . PMID 18548827.
↑  Masi, G. . CNS Drugs. 2004, 18 (14): 1031–52. PMID 15584771. doi:10.2165/00023210-200418140-00006.
↑  Marek, GJ; Carpenter, LL; McDougle, CJ; Price, LH. . Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. February 2003, 28 (2): 402–12. PMID 12589395. doi:10.1038/sj.npp.1300057.
↑  Posey, DJ; Guenin, KD; Kohn, AE; Swiezy, NB; McDougle, CJ. . J Child Adolesc Psychopharmacol. 2001, 11 (3): 267–77. PMID 11642476. doi:10.1089/10445460152595586.
↑  Coskun, M; Karakoc, S; Kircelli, F; Mukaddes, NM. . J Child Adolesc Psychopharmacol. April 2009, 19 (2): 203–6. PMID 19364298. doi:10.1089/cap.2008.020.
↑  Kumar, R; Sachdev, PS. . Current Opinion in Psychiatry. May 2009, 22 (3): 293–99  [2015-08-31]. PMID 19378382. doi:10.1097/YCO.0b013e32832a16da. （原始内容存档于2013-05-09）.
↑  Hieber, R; Dellenbaugh, T; Nelson, LA. . Annals of Pharmacotherapy. June 2008, 42 (6): 841–6. PMID 18460588. doi:10.1345/aph.1K672.
↑  Graves, SM; Rafeyan, R; Watts, J; Napier, TC. . Pharmacology & Therapeutics. December 2012, 136 (3): 343–353. PMC 3483434 . PMID 22960395. doi:10.1016/j.pharmthera.2012.08.013.
↑  Ritsner, MS. . Springer Science+Business Media Dordrecht. 2013  [2015-08-31]. ISBN 9789400758056. （原始内容存档于2020-08-21）.
↑  Vidal, C; Reese, C; Fischer, BA; Chiapelli, J; Himelhoch, S. . Clinical Schizophrenia & Related Psychoses (Walsh Medical Media). March 2013: 1–24. ISSN 1935-1232. PMID 23491969. doi:10.3371/CSRP.VIRE.030813.
↑  Tagai, K; Nagata, T; Shinagawa, S; Tsuno, N; Ozone, M; Nakayama, K. . Psychogeriatrics. June 2013, 13 (2): 103–107. PMID 23909968. doi:10.1111/j.1479-8301.2012.00432.x.
↑  Taylor, D; Paton, C; Shitij, K. . West Sussex: Wiley-Blackwell. 2012. ISBN 978-0-470-97948-8.
↑  Pharmacological Interventions: 10.14. Clinical Practice Recommendations （页面存档备份，存于）. National Collaborating Centre for Mental Health/British Psychological Society. 2010.
↑  Pharmacological Interventions: Third-Generation Antidepressants: 10.8.3. Mirtazapine. （页面存档备份，存于） National Collaborating Centre for Mental Health/British Psychological Society. 2010.
1 2  Watanabe, Norio; Omori, Ichiro M; Nakagawa, Atsuo; Cipriani, Andrea; Barbui, Corrado; Churchill, Rachel; Furukawa, Toshi A. . Cochrane Database of Systematic Reviews. 2011-12-07. PMC 4158430 . PMID 22161405. doi:10.1002/14651858.CD006528.pub2.
↑  Cipriani, Andrea; Furukawa, Toshi A; Salanti, Georgia; Chaimani, Anna; Atkinson, Lauren Z; Ogawa, Yusuke; Leucht, Stefan; Ruhe, Henricus G; Turner, Erick H; Higgins, Julian P T; Egger, Matthias; Takeshima, Nozomi; Hayasaka, Yu; Imai, Hissei; Shinohara, Kiyomi; Tajika, Aran; Ioannidis, John P A; Geddes, John R. . The Lancet. 2018, 391 (10128): 1357–1366. PMC 5889788 . PMID 29477251. doi:10.1016/S0140-6736(17)32802-7.
↑  Thompson, Chris. . Human Psychopharmacology. 2002,. 17 Suppl 1: S27–32. ISSN 0885-6222. PMID 12404667. doi:10.1002/hup.386.
1 2  Taylor, David; Paton, Carol; Kapur, Shitij. . Chichester: Wiley-Blackwell. 2012-04-02. ISBN 978-0-470-97948-8.
1 2  Fawcett, J.; Barkin, R. L. . Journal of Affective Disorders. 1998, 51 (3): 267–285. ISSN 0165-0327. PMID 10333982. doi:10.1016/s0165-0327(98)00224-9.
↑  Möller, Hans-Jürgen. . European Archives of Psychiatry and Clinical Neuroscience. 2006, 256 (8): 476–496. ISSN 0940-1334. PMID 17143567. doi:10.1007/s00406-006-0689-8.
↑  Abo-Zena, R. A.; Bobek, M. B.; Dweik, R. A. . Pharmacotherapy. 2000, 20 (4): 476–478. ISSN 0277-0008. PMID 10772378. doi:10.1592/phco.20.5.476.35061.
↑  《米氮平片说明书》，山德士（中国）制药有限公司。
1 2  Benazzi F (June 1998). "Mirtazapine withdrawal symptoms". Canadian Journal of Psychiatry. Revue canadienne de psychiatrie. 43 (5): 525. PMID 9653542.[不可靠的醫學來源?]
↑  Blier P (2001). "Pharmacology of rapid-onset antidepressant treatment strategies". The Journal of Clinical Psychiatry. 62 Suppl 15: 12–7. PMID 11444761.
↑  Vlaminck JJ, van Vliet IM, Zitman FG (March 2005). "[Withdrawal symptoms of antidepressants]". Nederlands Tijdschrift Voor Geneeskunde (in Dutch and Flemish). 149 (13): 698–701. PMID 15819135.
↑  Berigan TR (June 2001). "Mirtazapine-Associated Withdrawal Symptoms: A Case Report". Primary Care Companion to the Journal of Clinical Psychiatry. 3 (3): 143. doi:10.4088/PCC.v03n0307a. PMC 181176. PMID 15014614.[不可靠的醫學來源?]
↑  Klesmer J, Sarcevic A, Fomari V (August 2000). "Panic attacks during discontinuation of mirtazepine". Canadian Journal of Psychiatry. Revue canadienne de psychiatrie. 45 (6): 570–1. PMID 10986577.[不可靠的醫學來源?]
↑  MacCall C, Callender J (October 1999). "Mirtazapine withdrawal causing hypomania". The British Journal of Psychiatry. 175 (4): 390. doi:10.1192/bjp.175.4.390a. PMID 10789310.[不可靠的醫學來源?]
↑  Ali, Sherese; Milev, Roumen. . Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2003, 48 (4): 258–264. ISSN 0706-7437. PMID 12776393. doi:10.1177/070674370304800410.
1 2 3  Timmer, C. J.; Sitsen, J. M.; Delbressine, L. P. . Clinical Pharmacokinetics. 2000, 38 (6): 461–474. ISSN 0312-5963. PMID 10885584. doi:10.2165/00003088-200038060-00001. </nowiki>.
↑  .   [2018-10-19]. （原始内容存档于2021-01-10）.
↑  Fawcett J, Barkin RL (December 1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". Journal of Affective Disorders. 51 (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. PMID 10333982.
↑  Stahl SM (2008). Stahl's Essential Psychopharmacology Online: Print and Online. （页面存档备份，存于） Cambridge, UK: Cambridge University Press. ISBN 0-521-74609-4.
↑  Silva J, Mota J, Azevedo P (March 2016). "California rocket fuel: And what about being a first line treatment?". European Psychiatry. 33: S551. doi:10.1016/j.eurpsy.2016.01.2033.
↑  White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type" （页面存档备份，存于） (PDF). Journal of Medical Toxicology. 4 (4): 238–50. doi:10.1007/bf03161207. PMC 3550116. PMID 19031375.
↑  Fawcett J, Barkin RL (December 1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". Journal of Affective Disorders. 51 (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. PMID 10333982.
↑  Holzbach R, Jahn H, Pajonk FG, Mähne C (November 1998). "Suicide attempts with mirtazapine overdose without complications". Biological Psychiatry. 44 (9): 925–6. doi:10.1016/S0006-3223(98)00081-X. PMID 9807651.[不可靠的醫學來源?]
↑  Retz W, Maier S, Maris F, Rösler M (November 1998). "Non-fatal mirtazapine overdose". International Clinical Psychopharmacology. 13 (6): 277–9. doi:10.1097/00004850-199811000-00007. PMID 9861579
↑  Nikolaou P, Dona A, Papoutsis I, Spiliopoulou C, Maravelias C. . Clinical Toxicology. 2009, 47 (5): 436–510. S2CID 218861198. doi:10.1080/15563650902952273 .
↑  Baselt RC.  8th. Foster City, CA: Biomedical Publications. 2008: 1045–7. ISBN 978-0-9626523-7-0.
↑  Buckley, Nicholas A.; McManus, Peter R. . BMJ (Clinical research ed.). 2002-12-07, 325 (7376): 1332–1333. ISSN 1756-1833. PMC 137809 . PMID 12468481. doi:10.1136/bmj.325.7376.1332.
↑  Roth, BL; Driscol, J. "PDSP Ki Database" （页面存档备份，存于）. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
1 2  Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340(2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22  Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE (2006). "Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist". Bioorg. Med. Chem. 14 (13): 4526–34. doi:10.1016/j.bmc.2006.02.029. PMID 16517171.
1 2  Gillman PK (2007). "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated" （页面存档备份，存于）. Br. J. Pharmacol. 151 (6): 737–48. doi:10.1038/sj.bjp.0707253. PMC 2014120. PMID 17471183.
↑  Tatsumi M, Groshan K, Blakely RD, Richelson E (1997). "Pharmacological profile of antidepressants and related compounds at human monoamine transporters". Eur. J. Pharmacol. 340(2–3): 249–58. doi:10.1016/s0014-2999(97)01393-9. PMID 9537821.
1 2  Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE (2006). "Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist". Bioorg. Med. Chem. 14 (13): 4526–34. doi:10.1016/j.bmc.2006.02.029. PMID 16517171.
1 2 3 4 5 6 7 8 9  Fernández J, Alonso JM, Andrés JI, Cid JM, Díaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA (2005). "Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents". J. Med. Chem. 48(6): 1709–12. doi:10.1021/jm049632c. PMID 15771415.
1 2  Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R (2012). "Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics". Naunyn Schmiedebergs Arch. Pharmacol. 385 (2): 145–70. doi:10.1007/s00210-011-0704-0. PMID 22033803.
1 2 3  de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM (April 1988). "Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers". Neuropharmacology. 27(4): 399–408. doi:10.1016/0028-3908(88)90149-9. PMID 3419539.
1 2 3 4 5 6 7 8 9  Gillman PK (2006). "A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status". Hum Psychopharmacol. 21 (2): 117–25. doi:10.1002/hup.750. PMID 16342227.
1 2  Frazer A (1997). "Pharmacology of antidepressants". J Clin Psychopharmacol. 17 Suppl 1: 2S–18S. doi:10.1097/00004714-199704001-00002. PMID 9090573.
↑  Fisar Z, Hroudová J, Raboch J (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers". Neuro Endocrinology Letters. 31 (5): 645–56. PMID 21200377.
↑  Olianas MC, Dedoni S, Onali P (November 2012). "The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors". British Journal of Pharmacology. 167 (6): 1329–41. doi:10.1111/j.1476-5381.2012.02078.x. PMC 3504997. PMID 22708686.
↑  De Boer T, Nefkens F, Van Helvoirt A (February 1994). "The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo". European Journal of Pharmacology. 253 (1–2): R5–6. doi:10.1016/0014-2999(94)90778-1. PMID 7912194.[不可靠的醫學來源?]
1 2  Berendsen HH, Broekkamp CL (October 1997). "Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine". Psychopharmacology. 133 (3): 275–82. doi:10.1007/s002130050402. PMID 9361334.
↑  Nakayama K, Sakurai T, Katsu H (April 2004). "Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation". Brain Research Bulletin. 63 (3): 237–41. doi:10.1016/j.brainresbull.2004.02.007. PMID 15145142.[不可靠的医学来源?]
↑  Blier P, Abbott FV (January 2001). "Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain" (PDF). Journal of Psychiatry & Neuroscience. 26 (1): 37–43. PMC 1408043. PMID 11212592.
↑  Millan MJ (2005). "Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies". Thérapie. 60 (5): 441–60. doi:10.2515/therapie:2005065. PMID 16433010.
↑  Dekeyne A, Millan MJ (April 2009). "Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization". Psychopharmacology. 203 (2): 329–41. doi:10.1007/s00213-008-1259-8. PMID 18709360.
↑  Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (March 2000). "Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram". The European Journal of Neuroscience. 12 (3): 1079–95. doi:10.1046/j.1460-9568.2000.00982.x. PMID 10762339.
↑  Graves SM, Napier TC (June 2012). "SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats". BMC Neuroscience. 13 (1): 65. doi:10.1186/1471-2202-13-65. PMC 3441362. PMID 22697313.
1 2  Rose ME, Grant JE (2008). "Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions". Annals of Clinical Psychiatry. 20 (3): 145–55. doi:10.1080/10401230802177656. PMID 18633741.
1 2  Brackins T, Brahm NC, Kissack JC (December 2011). "Treatments for methamphetamine abuse: a literature review for the clinician". Journal of Pharmacy Practice. 24 (6): 541–50. doi:10.1177/0897190011426557. PMID 22095579.
1 2  Brensilver, Matthew; Heinzerling, Keith G.; Shoptaw, Steven. . Drug and Alcohol Review. 2013, 32 (5): 449–460. ISSN 1465-3362. PMC 4251965 . PMID 23617468. doi:10.1111/dar.12048.
↑  Kast, R. E. . Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2001, 9 (6): 469–470. ISSN 0941-4355. PMID 11585276. doi:10.1007/s005200000215. /ref>米氮平可作为一种廉价的止吐药以替代昂丹司琼。<ref>Kast, R. E.; Foley, K. F. . European Journal of Cancer Care. 2007, 16 (4): 351–354. ISSN 0961-5423. PMID 17587360. doi:10.1111/j.1365-2354.2006.00760.x.
↑  Costall, B.; Naylor, R. J.; Tyers, M. B. . Pharmacology & Therapeutics. 1990, 47 (2): 181–202. ISSN 0163-7258. PMID 2203069. doi:10.1016/0163-7258(90)90086-h.
↑  Caldis, Efstratios V.; Gair, Robert D. . Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2004, 49 (10): 707. ISSN 0706-7437. PMID 15560319. doi:10.1177/070674370404901014.
1 2 3 4 5  Gillman PK (June 2006). "A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action". Biological Psychiatry. 59 (11): 1046–51. doi:10.1016/j.biopsych.2005.11.016. PMID 16460699.
↑  Berling I, Isbister GK (2014). "Mirtazapine overdose is unlikely to cause major toxicity". Clin Toxicol. 52 (1): 20–4. doi:10.3109/15563650.2013.859264. PMC 3894718. PMID 24228948.
↑  Freijo Guerrero, J.; Tardón Ruiz de Gauna, L.; Gómez, J. J.; Aguilera Celorrio, L. . Revista Espanola De Anestesiologia Y Reanimacion. 2009, 56 (8): 515–516. ISSN 0034-9356. PMID 19994622. doi:10.1016/s0034-9356(09)70444-x.
↑  Butler, Meagan C.; Di Battista, Melissa; Warden, Matthew. . Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2010-08-16, 34 (6): 1128–1129. ISSN 1878-4216. PMID 20430060. doi:10.1016/j.pnpbp.2010.04.015.
↑  Decoutere L, De Winter S, Vander Weyden L, Spriet I, Schrooten M, Tournoy J, Fagard K (2012). "A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge". Int J Clin Pharm. 34 (5): 686–8. doi:10.1007/s11096-012-9666-7. PMID 22752315.
↑  Ansermot N, Hodel PF, Eap CB (2014). "Serotonin toxicity after addition of mirtazapine to escitalopram". J Clin Psychopharmacol. 34 (4): 540–1. doi:10.1097/JCP.0000000000000170. PMID 24977717.
↑  Wu CS, Tong SH, Ong CT, Sung SF (2015). "Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report". Acta Neurol Taiwan. 24 (4): 117–21. PMID 27333965.
↑  Hoes MJ, Zeijpveld JH (1996). "Mirtazapine as treatment for serotonin syndrome". Pharmacopsychiatry. 29 (2): 81. doi:10.1055/s-2007-979550. PMID 8741027.
↑  Shioda K, Nisijima K, Yoshino T, Kato S (2010). "Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome". Neurosci. Lett. 482 (3): 216–9. doi:10.1016/j.neulet.2010.07.039. PMID 20655983.
↑  qbal MM, Basil MJ, Kaplan J, Iqbal MT (2012). "Overview of serotonin syndrome". Ann Clin Psychiatry. 24 (4): 310–8. PMID 23145389.
↑  Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R, Matsuoka H, Yanai K (2013). "Histamine H₁ receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers". Psychopharmacology. 230(2): 227–34. doi:10.1007/s00213-013-3146-1. PMID 23728612.
↑  Burrows GD, Kremer CM (April 1997). "Mirtazapine: clinical advantages in the treatment of depression". Journal of Clinical Psychopharmacology. 17 Suppl 1: 34S–39S. doi:10.1097/00004714-199704001-00005. PMID 9090576.
1 2  Schatzberg, Alan F. (2009). "Chapter 21: Mirtazapine". In Schatzberg, Alan F.; Nemeroff, Charles B. The American Psychiatric Publishing Textbook of Psychopharmacology (4th ed.). Washington, D.C.: American Psychiatric Pub. ISBN 9781585623099.
1 2  Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 696–. ISBN 978-3-88763-075-1.
↑  I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. p. 183. ISBN 978-94-011-4439-1.
↑  Kaspersen, Frans M.; Van Rooij, Fons A. M.; Sperling, Eric G. M.; Wieringa, Joop H. (September 1989). "The synthesis of org 3770 labelled with 3H, 13C AND 14C". Journal of Labelled Compounds and Radiopharmaceuticals. 27 (9): 1055–1068. doi:10.1002/jlcr.2580270911.